Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of AV-101 Alone and with Probenecid in Healthy Subjects
NCT05280054Phase 1Unknown
- Sponsor
- Vistagen Therapeutics
- Start
- Dec 2021
- Primary completion
- Sep 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 4-chlorokynurenine in major depressive disorder (MDD) and neuropathic pain, sponsored by Vistagen Therapeutics. Primary endpoints: Plasma and CSF concentrations of 7-chloro-kynurenic acid at 24 hours and Plasma and CSF concentrations of 4-chloro-kynurenine at 24 hours. Status: unknown.
02
Drugs
4-chlorokynurenine
03
Conditions
major depressive disorder (MDD)neuropathic pain
Beyond the preview
Go deeper on NCT05280054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280054.